Many ICIs, including the PD-1 mAbs pembrolizumab, sintilimab, tislelizumab, and toripalimab, the PD-L1 mAbs sugemalimab and avelumab, and the dual-targeting anti-PD1/PD-L1 antibody IBI318, have been investigated for NKTCL (Table 2). The gene discussed is PDCD1; the disease is extranodal nasal NK/T cell lymphoma.